The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Sawhney Roger | Director | Grant(A) | 79K | — | $0 |
| Jun 8, 2026 | Beardsley Robert A | Director | Grant(A) | 79K | — | $0 |
| Feb 2, 2026 | Androski Lindsay | President and CEO, Director | Grant(A) | 28K | — | $0 |
| Feb 2, 2026 | Androski Lindsay | President and CEO, Director | Grant(A) | 72K | — | $0 |
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | Grant(A) | 74K | — | $0 |
| Feb 2, 2026 | Nguyen Tuan | Chief Financial Officer | Grant(A) | 188K | — | $0 |
| Aug 4, 2025 | Sawhney Roger | Director | Grant(A) | 158K | — | $0 |
| Mar 31, 2025 | Nguyen Tuan | Chief Financial Officer | Grant(A) | 750K | — | $0 |
| Mar 18, 2025 | Androski Lindsay | President and CEO, Director | Grant(A) | 310K | — | $0 |
| Mar 18, 2025 | Beardsley Robert A | Director | Grant(A) | 158K | — | $0 |
| Mar 18, 2025 | Hasija Anuj | Director | Grant(A) | 158K | — | $0 |
| Feb 14, 2025 | Sims Karen | Chief Medical Officer | Grant(A) | 49K | — | $0 |
| Feb 14, 2025 | Sims Karen | Chief Medical Officer | Grant(A) | 200K | — | $0 |
| Feb 14, 2025 | Hastings David C | Chief Financial Officer | Grant(A) | 90K | — | $0 |
| Feb 14, 2025 | Hastings David C | Chief Financial Officer | Grant(A) | 366K | — | $0 |
| Feb 14, 2025 | McElhaugh Michael J. | Interim President & CEO, Director | Grant(A) | 177K | — | $0 |
| Feb 14, 2025 | McElhaugh Michael J. | Interim President & CEO, Director | Grant(A) | 719K | — | $0 |
| Feb 14, 2025 | Naftzger J. Christopher | General Counsel and CCO | Grant(A) | 54K | — | $0 |
| Feb 14, 2025 | Naftzger J. Christopher | General Counsel and CCO | Grant(A) | 220K | — | $0 |
| Feb 4, 2025 | Naftzger J. Christopher | General Counsel and CCO | Sell(S) | 11K | $3.28 | $37K |
| Feb 4, 2025 | McElhaugh Michael J. | Interim President & CEO, Director | Sell(S) | 24K | $3.28 | $78K |
| Feb 4, 2025 | Sims Karen | Chief Medical Officer | Sell(S) | 19K | $3.28 | $63K |
| Feb 4, 2025 | Hastings David C | Chief Financial Officer | Sell(S) | 22K | $3.28 | $73K |
| Aug 14, 2024 | Manchester Keith S | Director | Sell(S) | 9K | $3.69 | $33K |
| Aug 14, 2024 | Manchester Keith S | Director | Option exercise(M) | 55K | $0.56 | $31K |
| Aug 14, 2024 | Manchester Keith S | Director | Option exercise(M) | 55K | — | $0 |
| May 23, 2024 | Torti Frank | Director | Grant(A) | 67K | — | $0 |
| May 23, 2024 | Rewolinski Melissa | Director | Grant(A) | 67K | — | $0 |
| May 23, 2024 | Meyers James R | Director | Grant(A) | 67K | — | $0 |
| May 23, 2024 | Henriques Richard C JR | Director | Grant(A) | 67K | — | $0 |
| May 23, 2024 | Manchester Keith S | Director | Grant(A) | 67K | — | $0 |
| May 23, 2024 | Burgess Daniel D | Director | Grant(A) | 67K | — | $0 |
| Feb 2, 2024 | McElhaugh Michael J. | Interim President & CEO, Director | Sell(S) | 10K | $2.31 | $23K |
| Feb 2, 2024 | Sofia Michael J. | Chief Scientific Officer | Sell(S) | 10K | $2.31 | $23K |
| Feb 2, 2024 | Hastings David C | Chief Financial Officer | Sell(S) | 10K | $2.31 | $22K |
| Feb 2, 2024 | Sims Karen | Chief Medical Officer | Sell(S) | 4K | $2.31 | $10K |
| Feb 1, 2024 | McElhaugh Michael J. | Interim President & CEO, Director | Grant(A) | 124K | — | $0 |
| Feb 1, 2024 | McElhaugh Michael J. | Interim President & CEO, Director | Grant(A) | 495K | — | $0 |
| Feb 1, 2024 | Sofia Michael J. | Chief Scientific Officer | Grant(A) | 110K | — | $0 |
| Feb 1, 2024 | Sofia Michael J. | Chief Scientific Officer | Grant(A) | 438K | — | $0 |
| Feb 1, 2024 | Hastings David C | Chief Financial Officer | Grant(A) | 113K | — | $0 |
| Feb 1, 2024 | Hastings David C | Chief Financial Officer | Grant(A) | 450K | — | $0 |
| Feb 1, 2024 | Sims Karen | Chief Medical Officer | Grant(A) | 101K | — | $0 |
| Feb 1, 2024 | Sims Karen | Chief Medical Officer | Grant(A) | 404K | — | $0 |
| Feb 1, 2024 | Naftzger J. Christopher | General Counsel and CCO | Grant(A) | 95K | — | $0 |
| Feb 1, 2024 | Naftzger J. Christopher | General Counsel and CCO | Grant(A) | 381K | — | $0 |
| Jul 12, 2023 | Rewolinski Melissa | Director | Grant(A) | 110K | — | $0 |
| Jul 10, 2023 | Naftzger J. Christopher | General Counsel and CCO | Grant(A) | 500K | — | $0 |
| Jul 10, 2023 | Sims Karen | Chief Medical Officer | Grant(A) | 154K | — | $0 |
| May 24, 2023 | Meyers James R | Director | Grant(A) | 55K | — | $0 |
| May 24, 2023 | Torti Frank | Director | Grant(A) | 55K | — | $0 |
| May 24, 2023 | Manchester Keith S | Director | Grant(A) | 55K | — | $0 |
| May 24, 2023 | Burgess Daniel D | Director | Grant(A) | 55K | — | $0 |
| May 24, 2023 | Henriques Richard C JR | Director | Grant(A) | 55K | — | $0 |
| Feb 1, 2023 | Howard Elizabeth | EVP, GC, Compliance | Grant(A) | 70K | — | $0 |
| Feb 1, 2023 | Howard Elizabeth | EVP, GC, Compliance | Grant(A) | 279K | — | $0 |
| Feb 1, 2023 | Collier William H. | President and CEO, Director | Grant(A) | 217K | — | $0 |
| Feb 1, 2023 | Collier William H. | President and CEO, Director | Grant(A) | 866K | — | $0 |
| Feb 1, 2023 | Hastings David C | Chief Financial Officer | Grant(A) | 79K | — | $0 |
| Feb 1, 2023 | Hastings David C | Chief Financial Officer | Grant(A) | 316K | — | $0 |
| Feb 1, 2023 | Sofia Michael J. | Chief Scientific Officer | Grant(A) | 82K | — | $0 |
| Feb 1, 2023 | Sofia Michael J. | Chief Scientific Officer | Grant(A) | 329K | — | $0 |
| Feb 1, 2023 | McElhaugh Michael J. | Chief Business Officer | Grant(A) | 84K | — | $0 |
| Feb 1, 2023 | McElhaugh Michael J. | Chief Business Officer | Grant(A) | 335K | — | $0 |
| May 25, 2022 | Manchester Keith S | Director | Grant(A) | 41K | — | $0 |
| May 25, 2022 | Tran Tram | Director | Grant(A) | 41K | — | $0 |
| May 25, 2022 | Torti Frank | Director | Grant(A) | 41K | — | $0 |
| May 25, 2022 | Meyers James R | Director | Grant(A) | 41K | — | $0 |
| May 25, 2022 | Burgess Daniel D | Director | Grant(A) | 41K | — | $0 |
| May 25, 2022 | Henriques Richard C JR | Director | Grant(A) | 41K | — | $0 |
| Jan 20, 2022 | McElhaugh Michael J. | Chief Business Officer | Grant(A) | 326K | $2.81 | $916K |
| Jan 20, 2022 | Picchio Gaston | Chief Development Officer | Grant(A) | 257K | $2.81 | $721K |
| Jan 20, 2022 | Sofia Michael J. | Chief Scientific Officer | Grant(A) | 285K | $2.81 | $801K |
| Jan 20, 2022 | Howard Elizabeth | Chief Compliance Officer | Grant(A) | 238K | $2.81 | $667K |
| Jan 20, 2022 | Hastings David C | Chief Financial Officer | Grant(A) | 285K | $2.81 | $801K |
| Jan 20, 2022 | Collier William H. | President and CEO, Director | Grant(A) | 788K | $2.81 | $2.2M |
| Dec 1, 2021 | Sofia Michael J. | Chief Scientific Officer | Sell(S) | 200K | $5.09 | $1.0M |
| Nov 9, 2021 | Tran Tram | Director | Grant(A) | 44K | — | $0 |
| Oct 18, 2021 | Roivant Sciences Ltd. | 10% Owner | Conversion(C) | 22.8M | — | — |
| Oct 18, 2021 | Roivant Sciences Ltd. | 10% Owner | Conversion(C) | 1.2M | — | — |
| Jun 3, 2021 | Burgess Daniel D | Director | Grant(A) | 22K | — | $0 |
| Jun 3, 2021 | Henriques Richard C JR | Director | Grant(A) | 22K | — | $0 |
| Jun 3, 2021 | Meyers James R | Director | Grant(A) | 22K | — | $0 |
| Jun 3, 2021 | Manchester Keith S | Director | Grant(A) | 22K | — | $0 |
| Jun 3, 2021 | Cheng Andrew | Director | Grant(A) | 22K | — | $0 |
| Jun 3, 2021 | Torti Frank | Director | Grant(A) | 22K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).